i-SPOT-d study to hunt depression biomarkers; MDxHealth has launched ConfirmMDx test for prostate cancer;

> The International Study to Predict Optimized Treatment of Depression (i-SPOT-d) is the largest ever study to evaluate characteristics and treatments of depression, and the researchers hope to discover markers to predict response to antidepressants. Press release

> Proteins in a drop of joint fluid could mark osteoarthritis risk. Article

> DNA copy number variations could predict prostate cancer relapse risk. Article

> MDxHealth has launched ConfirmMDx for prostate cancer; an epigenetic test to help identify men who may be able to avoid repeat biopsies. Press release

> Changes in the diameter of blood vessels in the eye look to be a useful pointer to cardiovascular disease in African-Americans with Type 1 diabetes. Article | Abstract

> DNA methylation has potential to diagnose prostate cancer and predict recurrence. Abstract | Press release

> KineMed and CHDI Foundation collaborate to develop new biomarkers of disease progression for Huntington's disease. Press release

> Immune cell activity could mark chronic fatigue syndrome and myalgic encephalomyelitis. Abstract

> A readily available urine dipstick test for protein is an accurate predictor of renal failure in sepsis patients. Press release

> MicroSCALE screening has found genetic modifiers that alter therapeutic responses to treatments in melanoma. Abstract

> Overexpression of a microRNA could point to a poor prognosis in acute leukemia. Press release | Abstract

> Nodal has potential as a prognostic and predictive biomarker in breast cancer. Abstract

> The microRNA miR-181d predicts response to temozolomide in glioblastoma. Abstract

> A 15-gene-expression-profiling (GEP) assay predicts the risk of metastasis in posterior uveal melanomas (eye cancers). Press release | Abstract

And Finally… NCCN Foundation has awarded one of the second series of Young Investigator Awards to Piero Dalerba of Stanford Cancer Institute for evaluation of CDX2 as a predictive biomarker in colon cancer. Press release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.